Can-Fite Biopharma Ltd ADR (AMEX:CANF) shares, rose in value on Thursday, April 16, with the stock price down by -2.44% to the previous day’s close as strong demand from buyers drove the stock to $1.20.
Actively observing the price movement in the last trading, the stock closed the session at $1.23, falling within a range of $1.18 and $1.25. The value of beta (5-year monthly) was 0.464. Referring to stock’s 52-week performance, its high was $4.69, and the low was $1.18. On the whole, CANF has fluctuated by -26.32% over the past month.
With the market capitalization of Can-Fite Biopharma Ltd ADR currently standing at about $12.54 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2024-Mar-27.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CANF’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CANF currently trading nearly -16.72% and -22.45% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.18, while the 7-day volatility ratio is showing 16.61% which for the 30-day chart, stands at 9.79%. Furthermore, Can-Fite Biopharma Ltd ADR (CANF)’s beta value is 1.17, and its average true range (ATR) is 0.15.
A comparison of Can-Fite Biopharma Ltd ADR (CANF) with its peers suggests the former has fared considerably weaker in the market. CANF showed an intraday change of -2.44% in last session, and over the past year, it shrunk by -42.31%%.
Data on historical trading for Can-Fite Biopharma Ltd ADR (AMEX:CANF) indicates that the trading volumes over the past 10 days have averaged 0.7 and over the past 3 months, they’ve averaged 280.91K. According to company’s latest data on outstanding shares, there are 4.53 million shares outstanding.
Can-Fite Biopharma Ltd ADR’s shares belong to company insiders and institutional investors own 1.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.38 million shares as on 2025-03-31, resulting in a short ratio of 1.14. According to the data, the short interest in Can-Fite Biopharma Ltd ADR (CANF) stood at 697.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.26 million. The stock has fallen by -26.15% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CANF stock heading into the next quarter.
